{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T03:53:40Z","timestamp":1780804420358,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2023.100782","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T17:28:06Z","timestamp":1676309286000},"page":"100782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Implementation and clinical benefit of DPYD genotyping in a Danish cancer population"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-0645","authenticated-orcid":false,"given":"N.H.","family":"Paulsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-0586","authenticated-orcid":false,"given":"P.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ewertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.N.","family":"Fruekilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-3299","authenticated-orcid":false,"given":"S.","family":"Feddersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-0721","authenticated-orcid":false,"given":"T.K.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Qvortrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-7187","authenticated-orcid":false,"given":"P.","family":"Damkier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.esmoop.2023.100782_bib2","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2023.100782_bib3","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.esmoop.2023.100782_bib4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis","volume":"26","author":"Sharma","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100782_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"10.1016\/j.esmoop.2023.100782_bib6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.100782_bib7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/0284186X.2022.2132117","article-title":"Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations","volume":"61","author":"Paulsen","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2023.100782_bib8","first-page":"1603","article-title":"Ethnic diversity of DPD activity and the DPYD gene: review of the literature","volume":"14","author":"White","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.esmoop.2023.100782_bib10","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20375","article-title":"Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy","volume":"150","author":"Hamzic","year":"2020","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100782_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bcpt.13782","article-title":"DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview","volume":"131","author":"Paulsen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100782_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","article-title":"Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100782_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity: DPYD and fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2014","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100782_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","article-title":"DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial","volume":"2","author":"Boige","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100782_bib16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/cts.12981","article-title":"Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events","volume":"14","author":"Wigle","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"19","key":"10.1016\/j.esmoop.2023.100782_bib18","first-page":"1446","article-title":"[Establishing the Danish CancerBiobank]","volume":"172","author":"Modin","year":"2010","journal-title":"Ugeskr Laeger"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100782_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","article-title":"A\u00a0comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","volume":"123","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100782_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study","volume":"112","author":"de With","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100782_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100782_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/10781552211049144","article-title":"Potential added value of combined DPYD\/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity","volume":"29","author":"Ockeloen","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100782_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.100782_bib25","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/bcp.13719","article-title":"Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers: food effect-study on U and DHU levels","volume":"84","author":"Henricks","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100782_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","volume":"88","author":"Gaible","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100782_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC\u2013MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100782_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1758834012441049","article-title":"Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle","volume":"4","author":"Cubero","year":"2012","journal-title":"Ther Adv Med Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:12Z","timestamp":1761856152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2059702923000029"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100782","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation and clinical benefit of DPYD genotyping in a Danish cancer population","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100782"}}